1 김상현, "이상지질혈증의 약물치료" 대한의사협회 59 (59): 366-373, 2016
2 Newman CB, "statin safety and associated adverse events : a scientific statement from the American heart association" 39 : e38-e81, 2019
3 Backes JM, "Statin-associated muscle symptoms-Managing the highly intolerant" 11 : 24-33, 2017
4 Tomlinson B, "Statin intolerance-an Asian perspective" 27 : 485-488, 2020
5 Chan JC, "Safety of atorvastatin in Asian patients within clinical trials" 34 : 431-440, 2016
6 Joy TR, "N-of-1(single-patient)trials for statin-related myalgia" 160 : 301-310, 2014
7 Collins R, "Interpretation of the evidence for the efficacy and safety of statin therapy" 388 : 2532-2561, 2016
8 Kim SH, "Efficacy and tolerability of a generic and a branded formulation of atorvastatin 20 mg/d in hypercholesterolemic Korean adults at high risk for cardiovascular disease : a multicenter, prospective, randomized, double-blind, double-dummy clinical trial" 32 : 1896-1905, 2010
9 The Korean Society of Lipid & Atherosclerosis, "Dyslipidemia fact sheets in Korea"
10 Mancini GB, "Diagnosis, prevention, and management of statin adverse effects and intolerance : Canadian consensus working group update(2016)" 32 : S35-S65, 2016
1 김상현, "이상지질혈증의 약물치료" 대한의사협회 59 (59): 366-373, 2016
2 Newman CB, "statin safety and associated adverse events : a scientific statement from the American heart association" 39 : e38-e81, 2019
3 Backes JM, "Statin-associated muscle symptoms-Managing the highly intolerant" 11 : 24-33, 2017
4 Tomlinson B, "Statin intolerance-an Asian perspective" 27 : 485-488, 2020
5 Chan JC, "Safety of atorvastatin in Asian patients within clinical trials" 34 : 431-440, 2016
6 Joy TR, "N-of-1(single-patient)trials for statin-related myalgia" 160 : 301-310, 2014
7 Collins R, "Interpretation of the evidence for the efficacy and safety of statin therapy" 388 : 2532-2561, 2016
8 Kim SH, "Efficacy and tolerability of a generic and a branded formulation of atorvastatin 20 mg/d in hypercholesterolemic Korean adults at high risk for cardiovascular disease : a multicenter, prospective, randomized, double-blind, double-dummy clinical trial" 32 : 1896-1905, 2010
9 The Korean Society of Lipid & Atherosclerosis, "Dyslipidemia fact sheets in Korea"
10 Mancini GB, "Diagnosis, prevention, and management of statin adverse effects and intolerance : Canadian consensus working group update(2016)" 32 : S35-S65, 2016
11 Kim SH, "Assessment of the efficacy and tolerability of 2 formulations of atorvastatin in Korean adults with hypercholesterolemia : a multicenter, prospective, open-label, randomized trial" 35 : 77-86, 2013
12 Rosenson RS, "An assessment by the statin muscle safety task force : 2014 update" 8 : S58-, 2014
13 Kim JB, "A randomized, open-label, parallel, multi-center Phase IV study to compare the efficacy and safety of atorvastatin 10 and 20 mg in high-risk Asian patients with hypercholesterolemia" 16 : e0245481-, 2021
14 Chien SC, "2019 Taiwan Society of Lipids and Atherosclerosis expert consensus statement on statin intolerance" 118 : 1385-1392, 2019
15 이은정 ; 김현창 ; 김재현 ; 이은영 ; 김병진 ; 김은미 ; 송윤주 ; 임정현 ; 김혜진 ; 최성훈 ; 문민경 ; 나진오 ; 박광열 ; 오미선 ; 한상엽 ; 노정현 ; 이경희 ; 이상학 ; 홍순철 ; 정인경, "2018 Guidelines for the Management of Dyslipidemia in Korea" 한국지질동맥경화학회 8 (8): 78-131, 2019
16 Catapano AL, "2016 ESC/EAS guidelines for the management of dyslipidaemias" 37 : 2999-3058, 2016